Cancer Family
Lipomatous Neoplasm
CI-CAN-00000216Explore in graph →
Non-malignant55 active trials1 approved drugs9 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000216Explore in graph →
Clinical trials
155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 |
| Mar 2, 2026 |
| clinicaltrials |
| NCT04794127 | Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.(TRABEPIO) | completed | Phase 2 | 10 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT02249949 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 15 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02978859 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | completed | Phase 2 | 70 | Leiden University Medical CenterOTHER | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02247544 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma(TRAVELL) | completed | Phase 2 | 105 | Italian Sarcoma GroupNETWORK | 1 | Nov 1, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | completed | Phase 2 | 52 | Grupo Espanol de Investigacion en SarcomasOTHER | 2 | Jul 23, 2020 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01209598 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | completed | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02249052 | Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma | completed | Phase 2 | 19 | Gerut, Zachary, M.D.INDIV | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01506596 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | completed | Phase 2 | 42 | Vector OncologyOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01613313 | A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | completed | Phase 2 | 14 | Zachary GerutINDIV | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00608842 | Phase 2 Study for the Treatment of Superficial Lipomas | completed | Phase 2 | 62 | Kythera BiopharmaceuticalsINDUSTRY | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00624416 | Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas | completed | Phase 1 / Phase 2 | 10 | Pennington Biomedical Research CenterOTHER | 1 | Dec 21, 2015 | clinicaltrials |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | completed | Phase 2 | 271 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 8 | Sep 8, 2014 | clinicaltrials |
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | completed | Phase 2 | 29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 3 | May 7, 2014 | clinicaltrials |
| NCT00792766 | Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) | completed | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00400569 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 28, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials